Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

15 Jan 2012

Abstract excerpt

To model the heterogeneity of breast cancer as observed in the clinic, we employed an ex vivo model of breast tumor tissue. This methodology maintained the histological integrity of the tumor tissue in unselected breast cancers, and importantly, the explants retained key molecular markers that are currently used to guide breast cancer treatment (e.g., ER and Her2 status). The primary tumors displayed the expected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22767154
DOI: 10.4161/cc.21195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumorsPMID 22767154Read ↗

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsSemantic proximity Read ↗

Patient‐Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational MedicineSemantic proximity Read ↗

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.Semantic proximity Read ↗

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancerSemantic proximity Read ↗

Fibroblasts from metastatic sites induce broad-spectrum drug desensitization via modulation of mitochondrial primingSemantic proximity Read ↗

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21Semantic proximity Read ↗

An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapySemantic proximity Read ↗

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type TumorsSemantic proximity Read ↗

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionSemantic proximity Read ↗

Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.Semantic proximity Read ↗

A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissueSemantic proximity Read ↗

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.